CAR T-cell therapy

CAR T-cell therapy (CAR T therapy) is a cancer immunotherapy treatment. It uses some of your own blood cells to treat cancer.

What is CAR T-cell therapy?

CAR T-cell therapy is a treatment that uses some of your own blood cells to treat cancer. It is used to treat some types of blood cancer. It may sometimes be used to treat other cancers or conditions as part of a clinical trial.

CAR T-cell therapy is an intensive treatment. It can have serious side effects. If your doctor recommends it as part of your treatment, they will discuss the possible benefits and disadvantages with you.

Currently, it is only available in a few specialist hospitals. This means you may have treatment in a hospital some distance from your home.

Related pages

How does CAR T-cell therapy work?

CAR T-cell therapy is a type of immunotherapy. This means it uses the body’s immune system to treat cancer. The immune system helps protect the body from infection or abnormal cells such as cancer cells.

CAR T-cell therapy works by changing the genetic material of some of the body’s immune cells. This is to make them better at fighting cancer cells. White blood cells called T-cells or T-lymphocytes are collected from the blood. They are changed to help them recognise and attack cancer cells.

CAR T stands for chimeric antigen receptor T-cell. This describes how the cells have been changed to make your treatment. Another name for CAR T-cell therapy is adoptive cellular therapy.

You may see CAR T-cell therapy written in different ways. These terms all refer to the same treatment. In this information we use the term CAR T-cell therapy.

Having CAR T-cell therapy

It takes several weeks to make CAR T-cell therapy. Here are the steps involved:

Collecting your T-cells

T-cells are taken from your blood. This process is called leukapheresis. It usually takes about 3 to 6 hours. A nurse puts a short, thin tube (cannula) into a vein in each arm. Some people have a cannula put into a vein in the groin (femoral line). Or if you have a central line, the nurse may use 2 ports on your central line.

The lines connect to tubes. These connect to a machine called a cell separator. Blood goes into the cell separator. This removes the T-cells from your blood. It then returns the blood to you.

Making the CAR T-cells

The collected T-cells are sent to a laboratory. At the lab, the cells are changed so that they are able to recognise cancer cells. The changed T-cells are called CAR T-cells. The number of CAR T-cells is then increased (expanded) until there are enough for your treatment. This takes 3 to 5 weeks.

CAR T-cells are carefully made under strict conditions. But sometimes the process fails to make a treatment. If this happens, your cancer team will talk to you about your options.

Waiting for treatment to be made

While the CAR T-cells are being made, you may need additional treatments to keep the cancer under control. This is called bridging. It can involve cancer drugs or radiotherapy or both. Your cancer team will explain if you need bridging treatments.

Getting ready for treatment

When they are ready, the CAR T-cells are sent back to the hospital where you will have the treatment. To prepare your body for CAR T-cell therapy, you will have 3 to 5 days of chemotherapy. This is called lymphodepletion. It reduces the white blood cells in the body. This allows the CAR T-cells to be effective.

Having the CAR T-cells

You have a single dose of the treatment during a stay in hospital. The CAR T-cells are put back into your bloodstream, usually through a drip. It takes about 10 to 20 minutes. 

One of the ingredients in the treatment creates a strong sweetcorn smell while the treatment is being given. Once in your body, the CAR T-cells will begin to attack the lymphoma cells.

After treatment

You usually stay in hospital for at least 10 days after the CAR T-cell drip. Your cancer team will monitor you closely for side effects and treat these as needed.

They will tell you when it is safe for you to go home. They will also make sure you have the support you need to be safe at home. They usually ask you to stay near the hospital for the first few weeks and have someone with you for the first month. They will explain about any support available in your local area. They will also tell you about the follow-up appointments you need.

Car T-cell therapy flowchart

 

Timeline showing the steps of CAR T-cell therapy, from collecting T cells, to making the treatment, having chemotherapy, receiving the CAR T-cells, and staying in hospital for monitoring.
Image: This diagram shows the steps you go through when you have CAR T-cell therapy. It is set out as a simple timeline, so you can see what happens first and what comes next. At the start, your T cells are collected from your blood. This takes between 3 and 6 hours. The next part of the timeline covers the following 3 to 5 weeks. During this time, your T cells are sent to a specialist lab. The lab changes them into CAR T-cells, which are your personalised treatment. When they are ready, they are sent back to the hospital. Some people need what is called bridging treatment while they wait. This helps keep the cancer under control. You may also have more tests so your team can check how things are going. Before you have the CAR T-cells, you have chemotherapy for 5 to 6 days. This helps prepare your body for the treatment. The CAR T-cells are then given back into your bloodstream. This usually takes 10 to 20 minutes. The final part of the timeline shows that you stay in hospital for at least 10 days. Your healthcare team will check you closely and support you with any side effects.

 

When is CAR T-cell therapy used?

In the UK, CAR T-cell therapy is mainly used to treat 2 types of blood cancer – lymphoma and lymphoblastic leukaemia. It is used:

  • to treat some types of high grade lymphoma and some types of acute leukaemia
  • if these cancers have not responded to other treatments
  • if these cancers have come back.

You might have CAR T-cell therapy as part of a clinical trial. It is being studied as a treatment for myeloma and some other cancers and conditions.

There are several CAR T-cell therapy treatments available. Each one is used in different situations. Your cancer team can give you more information about any treatment you are offered. We have more information about the following CAR T-cell therapies:

Side effects of CAR T-cell therapy

When you are ready to go home, your cancer team will tell you about side effects that may develop. They will also give you a 24-hour phone number to contact them if you have side effects or feel unwell. This means you can be treated straight away if needed.

CAR T-cell therapy is a newer type of cancer treatment. This means we do not know about all the possible side effects or longer term risks.

We have listed some of the most common side effects below.

Cytokine release syndrome (CRS)

As the CAR T-cells find and recognise the cancer cells, chemical messengers called cytokines are released. Cytokines help your immune system attack the cancer cells. But large amounts can make you feel unwell with flu-like symptoms. This is called cytokine release syndrome or CRS.

Symptoms may be mild, but sometimes CRS can be more serious. If this happens, you may need monitoring or treatment in hospital until symptoms improve.

CRS usually happens within the first 10 days of treatment. But it can happen later. If you have any of the following symptoms after you go home, contact the hospital straight away on the 24-hour number:

  • a high temperature
  • a fast heart rate
  • dizziness
  • muscle or joint pain
  • diarrhoea
  • feeling sick or being sick
  • difficulty breathing.

Effects on the brain (ICANS)

This treatment can cause temporary effects on the brain. This is called neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS). The effects can be mild but may become more serious. You may need treatment to stop them getting worse. Some people will need treatment in intensive care until the symptoms improve.

ICANS usually happens within the first 4 to 8 weeks after treatment. It usually gets better within 1 to 2 weeks.

You must not drive or use heavy machinery for at least 8 weeks after this treatment. If you have any of the following symptoms after you go home, contact the hospital straight away on the 24-hour number:

  • difficulty speaking
  • difficulty writing or doing fiddly tasks, such as fastening buttons or tying shoelaces
  • confusion
  • reduced consciousness (being less alert)
  • tremors or shaking
  • loss of balance
  • headaches
  • seizures (fits).

Risk of infection

This treatment affects your body’s ability to fight infection. This may be a long term effect after treatment. You will be more likely to get infections and have a higher risk of serious illness from infection.

To reduce your risk, your doctor may give you antibiotics and other drugs during and after this treatment. But it is still important to get any infection treated as soon as possible. If you have any of the following symptoms, contact the hospital straight away on the 24-hour number:

  • a temperature above 37.5°C
  • a temperature below 36°C
  • you feel unwell, even with a normal temperature
  • you have symptoms of an infection.

Symptoms of an infection include:

  • feeling shivery and shaking
  • a sore throat
  • a cough
  • breathlessness
  • diarrhoea
  • needing to pass urine (pee) often, or discomfort when you pass urine.

It is important to follow any specific advice your cancer treatment team gives you.

Bruising and bleeding

This treatment can reduce the number of platelets in your blood. Platelets are cells that help the blood to clot.

If the number of platelets is low, you may bruise or bleed easily. You may have:

  • nosebleeds
  • bleeding gums
  • heavy periods
  • blood in your urine (pee) or stools (poo)
  • tiny red, brown or purple spots that may look like a rash – these spots can be harder to see if you have black or brown skin.

If you have any unexplained bruising or bleeding, contact the hospital straight away on the 24-hour number. You may need a drip to give you extra platelets. This is called a platelet transfusion.

Anaemia (low number of red blood cells)

This treatment can reduce the number of red blood cells in your blood. Red blood cells carry oxygen around the body. If the number of red blood cells is low, this is called anaemia. You may feel:

  • very low in energy
  • breathless
  • dizzy and light-headed.

If you have these symptoms, contact the hospital straight away on the 24-hour number. You may need treatment for anaemia. If you are very anaemic, you may need a drip to give you extra red blood cells. This is called a blood transfusion.

Second cancer

This treatment may increase your risk of developing a different type of cancer. The benefits of treatment usually far outweigh this risk. Your cancer team can talk to you about this.

Getting support

We understand that having treatment can be a difficult time for people. We are here to support you. If you want to talk, you can:

About our information

This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer.

  • References

    Below is a sample of the sources used in our lymphoma information. If you would like more information about the sources we use, please contact us at informationproductionteam@macmillan.org.uk

     

    Cwynarski K, Marzolini MAV, Barrington SF, et al. The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2019;185:402-9.

     

    Eyre TA, Bishton MJ, McCulloch R, et al. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(1):108–26.

     

    Ferreri AJM, Illerhaus G, Doorduijn K, et al., on behalf of the EHA and ESMO Guidelines Committees. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(6):491-507.

     

    Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196:507-22.

     

    Fox CP, Chaganti S, McIlroy G, et al. The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(4):1178–92.

     

    McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Br J Haematol. 2020;191:363-81.

     

    Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline. Br J Haematol. 2022;197:171–87.

     

    Walewska R, Eyre TA, Barrington S, et al. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. Br J Haematol. 2024;204(1):86–107.

Date reviewed

Reviewed: 01 November 2024
|
Next review: 01 November 2027
Trusted Information Creator - Patient Information Forum
Trusted Information Creator - Patient Information Forum

Our cancer information meets the PIF TICK quality mark.

This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.

The language we use


We want everyone affected by cancer to feel our information is written for them.


We want our information to be as clear as possible. To do this, we try to:

  • use plain English
  • explain medical words
  • use short sentences
  • use illustrations to explain text
  • structure the information clearly
  • make sure important points are clear.

We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.


You can read more about how we produce our information here.